1993
DOI: 10.1016/0378-5122(93)90056-n
|View full text |Cite
|
Sign up to set email alerts
|

Postmenopausal oestrogen replacement therapy with subcutaneous oestradiol implants

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
2
0

Year Published

1993
1993
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 23 publications
0
2
0
Order By: Relevance
“…The observed decrease in uterine size after menopause is likely explained by lower estrogen levels [24]. Because estrogen levels drop dramatically after menopause, substantial changes in uterine volume occur only after menopause [25].…”
Section: Discussionmentioning
confidence: 97%
“…The observed decrease in uterine size after menopause is likely explained by lower estrogen levels [24]. Because estrogen levels drop dramatically after menopause, substantial changes in uterine volume occur only after menopause [25].…”
Section: Discussionmentioning
confidence: 97%
“…Substantial changes occurred only after the menopause, when uterine and ovarian size, endometrial thickness and number of follicle‐like cystic structures/corpora lutea decreased. The decrease in uterine size after menopause is likely to be explained by a decrease in estrogen levels16, because estrogen levels drop dramatically postmenopause15. Shrinkage of the ovaries is likely to be explained by depletion of follicles, which is a slow process starting as early as in fetal life17 and accelerating at 38 years of age or when about 25 000 follicles remain18.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, expression of numerous hepatic substances whose synthesis is sensitive to estrogens will be increased. Subcutaneous alternatives with administration via pellets exist for humans as well [168], but are not very commonly used. The inclusion of a peroral Nutella ® group in Paper I was an attempt to address this issue and offer a possibility to bridge the gap between preclinical and clinical studies.…”
Section: The Clinical Situationmentioning
confidence: 99%